To evaluate safety and performance of the BioMimeâ?¢ Morph Sirolimus-Eluting Coronary Stent Systems in the treatment of patients with coronary artery blockage.

A multicenter, observational, real-world, safety and performance evaluation of BioMimeâ?¢ Morph Sirolimus-Eluting Coronary Stent System for coronary artery lesions. - BioMimeâ?¢ Morph

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2018/01/011230

Enrollment

400

Registered

2018-01-10

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery

Interventions

Intervention1: BioMimeâ?¢ Morph: BioMimeâ?¢ Morph Sirolimus Eluting Coronary Stent System Control Intervention1: NIL: NIL

Sponsors

Meril Life Sciences Pvt Ltd

Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients who have been treated with BioMime• Morph. 2. Patients who are contactable, willing to participate will be taken into the study by signing voluntary informed consent form.

Exclusion criteria

Exclusion criteria: 1. There are no exclusion criteria for this study.

Design outcomes

Primary

Measure	Time frame
Major Adverse Cardiac Events (MACE)Timepoint: 2 years follow up	—

Secondary

Measure	Time frame
Target vessel failure (TVF), Stent Thrombosis, Procedure Success, Device SuccessTimepoint: 2 years follow up	—

Countries

India

Contacts

Public ContactDr Ashok Thakkar

Meril Life Sciences Pvt Ltd

ashok.thakkar@merillife.com9879443584

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026